Apogee Therapeutics' drug APG777 met primary endpoints in clinical trials for the treatment of atopic dermatitis.
3 reports, 1 independent
Updated Aug 15
Gone quiet
- Reports
- 3
- Developments
- 4
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Apogee Therapeutics' drug APG777 met primary endpoints in clinical trials for the treatment of atopic dermatitis.
How it developed
Newest first. Tap a step to see who reported it.- Apogee Therapeutics conducted the Phase 2 APEX clinical trial for its anti-IL-13 antibody, APG777.Sub-event
Apogee Therapeutics' drug APG777 achieved primary endpoints in atopic dermatitis trials.1 source
- CEO confirms positive trial results for APG777 de-risk its path to regulatory approval.
- Apogee Therapeutics is continuing development of novel biologics for AD.
Coverage
Newest first; wire copies grouped- Simply Wall St.Apogee Therapeutics (APGE) Is Up 5.9% After Strong APG777 Phase 2 Data and Accelerated Plans Apogee Therapeutics recently reported positive 16-week results from its APEX Phase 2 Part A trial, with AP
- Unknown outlet
- Unknown outlet